- Home
- CG vs BIIB Comparison
CG vs BIIB Comparison
Compare CG & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CG
- BIIB
- Stock Information
- Founded
- CG 1987
- BIIB 1978
- Country
- CG United States
- BIIB United States
- Employees
- CG N/A
- BIIB N/A
- Industry
- CG Investment Managers
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- CG Finance
- BIIB Health Care
- Exchange
- CG Nasdaq
- BIIB Nasdaq
- Market Cap
- CG 21.1B
- BIIB 18.7B
- IPO Year
- CG 2012
- BIIB 1991
- Fundamental
- Price
- CG $59.18
- BIIB $149.16
- Analyst Decision
- CG Buy
- BIIB Buy
- Analyst Count
- CG 14
- BIIB 25
- Target Price
- CG $62.25
- BIIB $183.05
- AVG Volume (30 Days)
- CG 2.9M
- BIIB 1.6M
- Earning Date
- CG 10-31-2025
- BIIB 10-30-2025
- Dividend Yield
- CG 2.39%
- BIIB N/A
- EPS Growth
- CG N/A
- BIIB 31.67
- EPS
- CG 3.42
- BIIB 10.45
- Revenue
- CG $5,525,600,000.00
- BIIB $9,997,000,000.00
- Revenue This Year
- CG N/A
- BIIB $2.03
- Revenue Next Year
- CG $19.01
- BIIB N/A
- P/E Ratio
- CG $17.09
- BIIB $14.34
- Revenue Growth
- CG 99.03
- BIIB 3.36
- 52 Week Low
- CG $33.02
- BIIB $110.04
- 52 Week High
- CG $69.85
- BIIB $187.58
- Technical
- Relative Strength Index (RSI)
- CG 45.72
- BIIB 57.30
- Support Level
- CG $56.05
- BIIB $141.70
- Resistance Level
- CG $58.74
- BIIB $151.91
- Average True Range (ATR)
- CG 1.85
- BIIB 3.47
- MACD
- CG 0.08
- BIIB -0.11
- Stochastic Oscillator
- CG 52.69
- BIIB 69.93
About CG The Carlyle Group Inc.
Carlyle Group is one of the world's largest alternative-asset managers, with $465 billion in total AUM, including $325 billion in fee-earning AUM, at the end of June 2025. The company has three core business segments: global private equity, which includes its private equity, real estate, infrastructure, and natural resources offerings (with $165 billion in total AUM and $102 billion in fee-earning AUM), global credit ($203 billion/$163 billion), and investment/fund solutions, known as Carlyle AlphInvest ($97 billion/$60 billion). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving more than 3,100 active carry fund investors from 87 countries.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.